Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00373464 |
Recruitment Status :
Completed
First Posted : September 8, 2006
Last Update Posted : July 1, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hysterectomy Tubal Excision Ovariectomy Postoperative Pain | Drug: etoricoxib | Phase 3 |

Study Type : | Interventional (Clinical Trial) |
Enrollment : | 126 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic Gynaecologic Surgery With Expected Need of Post-operative Opioids |
Study Start Date : | March 2006 |
Actual Study Completion Date : | March 2007 |
- Equal opioid consumption in both groups postoperatively
- Equal visual analogue scale (VAS) and verbal rating scale (VRS) in the first 4 hours

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients (American Society of Anaesthesiologists [ASA] I and II) due for elective, laparoscopic gynaecologic surgery with the expected need for post-operative opioids: hysterectomy, removal of tube(s) and/or ovarium.
- Written informed consent.
- Weight between 50 and 120 kg.
Exclusion Criteria:
- Patients who use nonsteroidal anti-inflammatory agents (NSAIDs) in the last 48 hours (h) before surgery or are allergic to NSAIDs. Patients using steroids, anti-emetic drugs, or opioids in the last 48 h before surgery.
- Sensitivity to the study drug or its components.
- Cardiovascular risk conditions: heart failure, unstable hypertension, coronary artery disease (i.e. angina, previous myocardial infarction, previous coronary artery bypass surgery).
- Cerebrovascular disease.
- Other applicable exclusion criteria.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00373464
Norway | |
Ullevaal University Hospital | |
Oslo, Norway |
Study Director: | Johan Ræder, Prof.MD,PhD | Ullevaal University Hospital | |
Principal Investigator: | Harald Lenz, MD | Ullevaal University Hospital |
ClinicalTrials.gov Identifier: | NCT00373464 |
Other Study ID Numbers: |
2005-003078-92 |
First Posted: | September 8, 2006 Key Record Dates |
Last Update Posted: | July 1, 2011 |
Last Verified: | August 2005 |
Postoperative pain Opioid Etoricoxib |
Ketorolac Laparoscopic Surgery Surgical Procedures, Gynecologic |
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Etoricoxib Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics |
Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |